Heron Therapeutics Inc vs Weibo Corp — how do they compare? Heron Therapeutics Inc trades at $0.33 (market cap $63.41M), while Weibo Corp trades at $7.86 (market cap $1.93B). The key difference: Weibo Corp is far larger — about 30.4× Heron Therapeutics Inc's market cap, and Weibo Corp pays a 7.65% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | WB | |
|---|---|---|
Market Cap | $63.41M | $1.93B |
Sector | Health | Media |
52-Week High | $1.49 | $12.83 |
52-Week Low | $0.33 | $7.20 |
Enterprise Value | $161.31M | $1.20B |
Dividend Yield | — | 7.65% |
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Weibo (WB) trades at $7.94, up 0.76% today, with neutral technical signals and strong fundamental metrics including a low P/E of 5.55 and robust 21.15% net income margin. Recent earnings show three consecutive quarterly misses but Q2 2026 results are pending. The company maintains solid cash flow generation with $519M operating cash flow in 2025, while analyst sentiment is mixed with 45% buy ratings.
WB presents value opportunity with discounted valuation metrics and strong profitability, though competitive pressures from Douyin and WeChat create headwinds. The stock's 8% dividend yield and cash-rich balance sheet provide downside protection, but investor sentiment remains cautious pending Q2 earnings results on August 19, 2026.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →